ADRIAMYCIN PLUS ZINECARD V NO TREATMENT IN ADVANCED BREAST CA AFTER 6 CYCLES CAF

这项随机IIIb期双组试验的主要目的是 1）评价是否继续接受阿霉素和右雷佐生治疗 （具有心脏保护作用） 稳定或缓解的局部晚期或转移性乳腺癌患者 在接受六个疗程的一线CAF化疗后， 6个疗程后化疗中断的同类患者 2）是否继续使用这些药物治疗， 至疾病进展、发生CHF或死亡的时间，与 化疗中断的患者; 3）评估化疗对患者的影响， 体能状态、肿瘤相关症状和两种药物的安全性。

The primary objectives of this randomized Phase IIIb two armed trial are to 1) evaluate whether continuing therapy with Adriamycin and dexrazoxane (which is cardioprotective) prolongs time to progression in patients with locally advanced or metastatic breast cancer who are stable or in response after receiving six courses of front-line CAF chemotherapy compared to similar patients whose chemotherapy has been interrupted after 6 courses of chemotherapy; 2) whether continuing therapy with these agents prolongs time to disease progression, development of CHF, or death compared to patients who had chemotherapy interrrupted; 3) to evaluate the effect on performance status, tumor-related symptoms and safety of both agents.